Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;7(3):261-278.
doi: 10.3233/BLC-211536. eCollection 2021.

Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations

John Kim  1 , Harkanwal Randhawa  2 , David Sands  2 , Shahid Lambe  2   3 , Marco Puglia  4 , Pablo E Serrano  4 , Jehonathan H Pinthus  2   4
Affiliations
Review

Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations

John Kim et al. Bladder Cancer. .

Abstract

The incidence of liver cirrhosis is increasing worldwide. Patients with cirrhosis are generally at a higher risk of harbouring hepatic and non-hepatic malignancies, including bladder cancer, likely due to the presence of related risk factors such as smoking. Cirrhosis can complicate both the operative and non-surgical management of bladder cancer. For example, cirrhotic patients undergoing abdominal surgery generally demonstrate worse postoperative outcomes, and chemotherapy in patients with cirrhosis often requires dose reduction due to its direct hepatotoxic effects and reduced hepatic clearance. Multiple other considerations in the peri-operative management for cirrhosis patients with muscle-invasive bladder cancer must be taken into account to optimize outcomes in these patients. Unfortunately, the current literature specifically related to the treatment of cirrhotic bladder cancer patients remains sparse. We aim to review the literature on treatment considerations for this patient population with respect to perioperative, surgical, and adjuvant management.

Keywords: Bladder cancer; chemotherapy; cirrhosis; cystectomy; stomal varices.

PubMed Disclaimer

Conflict of interest statement

The authors (JK, HR, DS, SL, MP, PES, and JHP) have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Flow chart of suggested considerations for patients with muscle-invasive bladder cancer and cirrhosis. Developed at McMaster University. CTP: Child-Pugh-Turcotte; MELD: Model for End-Stage Liver Disease; TMT: Trimodal therapy; TURBT: Transurethral resection of bladder tumour.
See this image and copyright information in PMC

References

    1. Schuppan D, Afdhal NH. Liver Cirrhosis. Lancet. 2008;371:838–51. https://doi.org/ 10.1016/S0140-6736(08)60383-9. - DOI - PMC - PubMed
    1. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563–76. https://doi.org/ 10.1016/j.jhep.2017.10.020. - DOI - PubMed
    1. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17:717. https://doi.org/ 10.3390/ijms17050717. - DOI - PMC - PubMed
    1. Ratib S, Fleming KM, Crooks CJ, Walker AJ, West J. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol. 2015;110:1149–58. https://doi.org/ 10.1038/ajg.2015.191. - DOI - PubMed
    1. Sørensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjær L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark. Hepatology. 1998;28:921–5. https://doi.org/ 10.1002/hep.510280404. - DOI - PubMed

LinkOut - more resources